Literature DB >> 33817187

Intra-arterial Tirofiban in a Male Nonagenarian with Acute Ischemic Stroke: A Case Report.

Xianhui Ding1, Ao Gu1,2, Qian Yang1, Zhiming Zhou3, Xiaolei Shi3.   

Abstract

Nonagenarians with acute ischemic stroke tend to have a higher mortality and morbidity than younger patients. Tirofiban is a glycoprotein IIb/IIIa antagonist that has a therapeutic potential for ischemic stroke. Here, we provide a case report of a 93-year-old male patient with acute ischemic stroke. He presented with right-sided hemiparesis for 2 hours (National Institute of Health Stroke Scale, NIHSS = 23). Immediate treatment with endovascular tirofiban infusion achieved an improvement of intracranial blood flow and a progressively decreased NIHSS one day after admission (NIHSS = 16) and then seven days after admission (NIHSS = 7). After a follow-up of 90 days, the modified ranking score was 2. This case report suggests that endovascular application with tirofiban may be a favorable option for treating nonagenarians presenting with acute ischemic stroke and warrants further study.
© 2019 Xianhui Ding et al., published by De Gruyter.

Entities:  

Keywords:  Stroke; endovascular; intra-arterial; nonagenarian; tirofiban

Year:  2019        PMID: 33817187      PMCID: PMC7874810          DOI: 10.1515/biol-2019-0057

Source DB:  PubMed          Journal:  Open Life Sci        ISSN: 2391-5412            Impact factor:   0.938


  13 in total

1.  Probability of stroke: a risk profile from the Framingham Study.

Authors:  P A Wolf; R B D'Agostino; A J Belanger; W B Kannel
Journal:  Stroke       Date:  1991-03       Impact factor: 7.914

Review 2.  Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.

Authors:  Arturo Giordano; Giuseppe Musumeci; Anna D'Angelillo; Roberta Rossini; Giuseppe Biondi Zoccai; Stefano Messina; Enrico Coscioni; Simona Romano; Maria Fiammetta Romano
Journal:  Curr Drug Metab       Date:  2016       Impact factor: 3.731

3.  Instant reocclusion following mechanical thrombectomy of in situ thromboocclusion and the role of low-dose intra-arterial tirofiban.

Authors:  Dong-Hun Kang; Yong-Won Kim; Yang-Ha Hwang; Sung-Pa Park; Yong-Sun Kim; Seung Kug Baik
Journal:  Cerebrovasc Dis       Date:  2014-06-13       Impact factor: 2.762

4.  Endovascular treatment with tirofiban during the acute stage of cervical spinal cord infarction due to vertebral artery dissection.

Authors:  Yuanling Wu; Wenxian Li; Xiaomei Xie; Zhen Jing; Weibiao Lu; Li'an Huang
Journal:  J Spinal Cord Med       Date:  2018-01-11       Impact factor: 1.985

5.  Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial.

Authors:  Mario Siebler; Michael G Hennerici; Dietmar Schneider; Gerhard M von Reutern; Rüdiger J Seitz; Joachim Röther; Otto W Witte; Gerhard Hamann; Ulrich Junghans; Arno Villringer; Jochen B Fiebach
Journal:  Stroke       Date:  2011-08-18       Impact factor: 7.914

6.  Safety and efficacy of tirofiban combined with endovascular treatment in acute ischaemic stroke.

Authors:  X Pan; D Zheng; Y Zheng; P W L Chan; Y Lin; J Zou; J Zhou; J Yang
Journal:  Eur J Neurol       Date:  2019-03-19       Impact factor: 6.089

Review 7.  Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.

Authors:  Shawn King; Marintha Short; Cassidy Harmon
Journal:  Vascul Pharmacol       Date:  2015-07-15       Impact factor: 5.773

8.  Endovascular Stroke Treatment of Nonagenarians.

Authors:  M Möhlenbruch; J Pfaff; S Schönenberger; S Nagel; J Bösel; C Herweh; P Ringleb; M Bendszus; S Stampfl
Journal:  AJNR Am J Neuroradiol       Date:  2016-10-27       Impact factor: 3.825

Review 9.  History, Evolution, and Importance of Emergency Endovascular Treatment of Acute Ischemic Stroke.

Authors:  Jessalyn K Holodinsky; Amy Y X Yu; Zarina A Assis; Abdulaziz S Al Sultan; Bijoy K Menon; Andrew M Demchuk; Mayank Goyal; Michael D Hill
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

Review 10.  [Endovascular thrombectomy for ischemic stroke].

Authors:  B Kallmünzer; M Köhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-09-11       Impact factor: 0.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.